The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients

Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Yang, Xiangshan [verfasserIn] Li, Daotang Cheng, Shaomei Fan, Kaixi Sheng, Lijun Zhang, Jing Feng, Bin Xu, Zhongfa

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2014

Schlagwörter:	BMP2 Immunohistochemistry Glioma Prognosis

Anmerkung:	© International Society of Oncology and BioMarkers (ISOBM) 2014

Übergeordnetes Werk:	Enthalten in: Tumor biology - Amsterdam : IOS Press, 1987, 35(2014), 11 vom: 07. Aug., Seite 11091-11095
Übergeordnetes Werk:	volume:35 ; year:2014 ; number:11 ; day:07 ; month:08 ; pages:11091-11095

Links:	Volltext

DOI / URN:	10.1007/s13277-014-2424-9

Katalog-ID:	SPR031135218

Internformat


LEADER	01000caa a22002652 4500
001	SPR031135218
003	DE-627
005	20230519165003.0
007	cr uuu---uuuuu
008	201007s2014 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13277-014-2424-9 \|2 doi
035			\|a (DE-627)SPR031135218
035			\|a (SPR)s13277-014-2424-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Yang, Xiangshan \|e verfasserin \|4 aut
245	1	4	\|a The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © International Society of Oncology and BioMarkers (ISOBM) 2014
520			\|a Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target.
650		4	\|a BMP2 \|7 (dpeaa)DE-He213
650		4	\|a Immunohistochemistry \|7 (dpeaa)DE-He213
650		4	\|a Glioma \|7 (dpeaa)DE-He213
650		4	\|a Prognosis \|7 (dpeaa)DE-He213
700	1		\|a Li, Daotang \|4 aut
700	1		\|a Cheng, Shaomei \|4 aut
700	1		\|a Fan, Kaixi \|4 aut
700	1		\|a Sheng, Lijun \|4 aut
700	1		\|a Zhang, Jing \|4 aut
700	1		\|a Feng, Bin \|4 aut
700	1		\|a Xu, Zhongfa \|4 aut
773	0	8	\|i Enthalten in \|t Tumor biology \|d Amsterdam : IOS Press, 1987 \|g 35(2014), 11 vom: 07. Aug., Seite 11091-11095 \|w (DE-627)300897855 \|w (DE-600)1483579-4 \|x 1423-0380 \|7 nnns
773	1	8	\|g volume:35 \|g year:2014 \|g number:11 \|g day:07 \|g month:08 \|g pages:11091-11095
856	4	0	\|u https://dx.doi.org/10.1007/s13277-014-2424-9 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_22
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_63
912			\|a GBV_ILN_95
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_370
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4338
951			\|a AR
952			\|d 35 \|j 2014 \|e 11 \|b 07 \|c 08 \|h 11091-11095

Indexfelder

author_variant	x y xy d l dl s c sc k f kf l s ls j z jz b f bf z x zx
matchkey_str	article:14230380:2014----::hcreainfoeopoeeipoenwtpopon
hierarchy_sort_str	2014
publishDate	2014
allfields	10.1007/s13277-014-2424-9 doi (DE-627)SPR031135218 (SPR)s13277-014-2424-9-e DE-627 ger DE-627 rakwb eng Yang, Xiangshan verfasserin aut The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2014 Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. BMP2 (dpeaa)DE-He213 Immunohistochemistry (dpeaa)DE-He213 Glioma (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Li, Daotang aut Cheng, Shaomei aut Fan, Kaixi aut Sheng, Lijun aut Zhang, Jing aut Feng, Bin aut Xu, Zhongfa aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 35(2014), 11 vom: 07. Aug., Seite 11091-11095 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095 https://dx.doi.org/10.1007/s13277-014-2424-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_187 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 35 2014 11 07 08 11091-11095
spelling	10.1007/s13277-014-2424-9 doi (DE-627)SPR031135218 (SPR)s13277-014-2424-9-e DE-627 ger DE-627 rakwb eng Yang, Xiangshan verfasserin aut The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2014 Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. BMP2 (dpeaa)DE-He213 Immunohistochemistry (dpeaa)DE-He213 Glioma (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Li, Daotang aut Cheng, Shaomei aut Fan, Kaixi aut Sheng, Lijun aut Zhang, Jing aut Feng, Bin aut Xu, Zhongfa aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 35(2014), 11 vom: 07. Aug., Seite 11091-11095 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095 https://dx.doi.org/10.1007/s13277-014-2424-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_187 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 35 2014 11 07 08 11091-11095
allfields_unstemmed	10.1007/s13277-014-2424-9 doi (DE-627)SPR031135218 (SPR)s13277-014-2424-9-e DE-627 ger DE-627 rakwb eng Yang, Xiangshan verfasserin aut The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2014 Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. BMP2 (dpeaa)DE-He213 Immunohistochemistry (dpeaa)DE-He213 Glioma (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Li, Daotang aut Cheng, Shaomei aut Fan, Kaixi aut Sheng, Lijun aut Zhang, Jing aut Feng, Bin aut Xu, Zhongfa aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 35(2014), 11 vom: 07. Aug., Seite 11091-11095 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095 https://dx.doi.org/10.1007/s13277-014-2424-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_187 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 35 2014 11 07 08 11091-11095
allfieldsGer	10.1007/s13277-014-2424-9 doi (DE-627)SPR031135218 (SPR)s13277-014-2424-9-e DE-627 ger DE-627 rakwb eng Yang, Xiangshan verfasserin aut The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2014 Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. BMP2 (dpeaa)DE-He213 Immunohistochemistry (dpeaa)DE-He213 Glioma (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Li, Daotang aut Cheng, Shaomei aut Fan, Kaixi aut Sheng, Lijun aut Zhang, Jing aut Feng, Bin aut Xu, Zhongfa aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 35(2014), 11 vom: 07. Aug., Seite 11091-11095 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095 https://dx.doi.org/10.1007/s13277-014-2424-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_187 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 35 2014 11 07 08 11091-11095
allfieldsSound	10.1007/s13277-014-2424-9 doi (DE-627)SPR031135218 (SPR)s13277-014-2424-9-e DE-627 ger DE-627 rakwb eng Yang, Xiangshan verfasserin aut The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2014 Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. BMP2 (dpeaa)DE-He213 Immunohistochemistry (dpeaa)DE-He213 Glioma (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Li, Daotang aut Cheng, Shaomei aut Fan, Kaixi aut Sheng, Lijun aut Zhang, Jing aut Feng, Bin aut Xu, Zhongfa aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 35(2014), 11 vom: 07. Aug., Seite 11091-11095 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095 https://dx.doi.org/10.1007/s13277-014-2424-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_187 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 35 2014 11 07 08 11091-11095
language	English
source	Enthalten in Tumor biology 35(2014), 11 vom: 07. Aug., Seite 11091-11095 volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095
sourceStr	Enthalten in Tumor biology 35(2014), 11 vom: 07. Aug., Seite 11091-11095 volume:35 year:2014 number:11 day:07 month:08 pages:11091-11095
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	BMP2 Immunohistochemistry Glioma Prognosis
isfreeaccess_bool	false
container_title	Tumor biology
authorswithroles_txt_mv	Yang, Xiangshan @@aut@@ Li, Daotang @@aut@@ Cheng, Shaomei @@aut@@ Fan, Kaixi @@aut@@ Sheng, Lijun @@aut@@ Zhang, Jing @@aut@@ Feng, Bin @@aut@@ Xu, Zhongfa @@aut@@
publishDateDaySort_date	2014-08-07T00:00:00Z
hierarchy_top_id	300897855
id	SPR031135218
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031135218</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519165003.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13277-014-2424-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031135218</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13277-014-2424-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yang, Xiangshan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© International Society of Oncology and BioMarkers (ISOBM) 2014</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">BMP2</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunohistochemistry</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glioma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Daotang</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheng, Shaomei</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fan, Kaixi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sheng, Lijun</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Jing</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feng, Bin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Zhongfa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Tumor biology</subfield><subfield code="d">Amsterdam : IOS Press, 1987</subfield><subfield code="g">35(2014), 11 vom: 07. Aug., Seite 11091-11095</subfield><subfield code="w">(DE-627)300897855</subfield><subfield code="w">(DE-600)1483579-4</subfield><subfield code="x">1423-0380</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">day:07</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:11091-11095</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13277-014-2424-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="b">07</subfield><subfield code="c">08</subfield><subfield code="h">11091-11095</subfield></datafield></record></collection>
author	Yang, Xiangshan
spellingShingle	Yang, Xiangshan misc BMP2 misc Immunohistochemistry misc Glioma misc Prognosis The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
authorStr	Yang, Xiangshan
ppnlink_with_tag_str_mv	@@773@@(DE-627)300897855
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1423-0380
topic_title	The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients BMP2 (dpeaa)DE-He213 Immunohistochemistry (dpeaa)DE-He213 Glioma (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213
topic	misc BMP2 misc Immunohistochemistry misc Glioma misc Prognosis
topic_unstemmed	misc BMP2 misc Immunohistochemistry misc Glioma misc Prognosis
topic_browse	misc BMP2 misc Immunohistochemistry misc Glioma misc Prognosis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Tumor biology
hierarchy_parent_id	300897855
hierarchy_top_title	Tumor biology
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)300897855 (DE-600)1483579-4
title	The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
ctrlnum	(DE-627)SPR031135218 (SPR)s13277-014-2424-9-e
title_full	The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
author_sort	Yang, Xiangshan
journal	Tumor biology
journalStr	Tumor biology
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	11091
author_browse	Yang, Xiangshan Li, Daotang Cheng, Shaomei Fan, Kaixi Sheng, Lijun Zhang, Jing Feng, Bin Xu, Zhongfa
container_volume	35
format_se	Elektronische Aufsätze
author-letter	Yang, Xiangshan
doi_str_mv	10.1007/s13277-014-2424-9
title_sort	correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
title_auth	The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
abstract	Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. © International Society of Oncology and BioMarkers (ISOBM) 2014
abstractGer	Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. © International Society of Oncology and BioMarkers (ISOBM) 2014
abstract_unstemmed	Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target. © International Society of Oncology and BioMarkers (ISOBM) 2014
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_187 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338
container_issue	11
title_short	The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients
url	https://dx.doi.org/10.1007/s13277-014-2424-9
remote_bool	true
author2	Li, Daotang Cheng, Shaomei Fan, Kaixi Sheng, Lijun Zhang, Jing Feng, Bin Xu, Zhongfa
author2Str	Li, Daotang Cheng, Shaomei Fan, Kaixi Sheng, Lijun Zhang, Jing Feng, Bin Xu, Zhongfa
ppnlink	300897855
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s13277-014-2424-9
up_date	2024-07-03T22:10:57.108Z
_version_	1803597546373775360
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031135218</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519165003.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13277-014-2424-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031135218</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13277-014-2424-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yang, Xiangshan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© International Society of Oncology and BioMarkers (ISOBM) 2014</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Glioma is the most common type of human intracranial cancers and has poor prognosis. Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751–9, 2014). Here, we aimed to investigate the correlation of BMP2 with patient prognosis as well as pathological indicators. Immunohistochemistry was used to test BMP2 proteins in 45 gliomas of distinct malignancy grade, and Kaplan–Meier survival analysis was performed to assess prognostic significance. BMP2 protein was also detected in cell lines by Western blot. We observed that BMP2 protein was stained in 44.4 % (20 out of 45) of all glioma tissues, including 32.1 % of low-grade (I + II) gliomas and 52.9 % of high-grade (III + IV) gliomas. Grade IV gliomas potently expressed BMP2 proteins. Western blot showed BMP2 protein expressed in cell lines NHA, A172, T98G, U87, and U251. In addition, BMP2 expression was significantly associated with WHO grade (p = 0.024). According to log-rank test and Cox regression model, BMP2 can be suggested as an independent prognostic factor, apart from WHO grade. Taken together, BMP2 is differently highly expressed in different grades of gliomas and correlated to WHO grade. BMP2 also independently indicates poor prognosis in old glioma patients, which is indicative of an effectively therapeutic target.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">BMP2</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunohistochemistry</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glioma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Daotang</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheng, Shaomei</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fan, Kaixi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sheng, Lijun</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Jing</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feng, Bin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Zhongfa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Tumor biology</subfield><subfield code="d">Amsterdam : IOS Press, 1987</subfield><subfield code="g">35(2014), 11 vom: 07. Aug., Seite 11091-11095</subfield><subfield code="w">(DE-627)300897855</subfield><subfield code="w">(DE-600)1483579-4</subfield><subfield code="x">1423-0380</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">day:07</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:11091-11095</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13277-014-2424-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="b">07</subfield><subfield code="c">08</subfield><subfield code="h">11091-11095</subfield></datafield></record></collection>
score	7.3988447

Nicht das Richtige dabei?

Schreiben Sie uns!

The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?